explore -WSS

explore

author：focus 2025-08-27 16:47:33 - browse：133

The Johnson and Johnson booth at ESMO in Madrid. — The Johnson & Johnson booth at ESMO 2023. Andrew Joseph/STAT

MADRID — A competition has been brewing between two pharma titans — Johnson & Johnson and AstraZeneca — to gain an edge in the market for targeted lung cancer treatments. A primetime presentation here Monday amounted to the latest salvo.

At the annual meeting of the European Society for Medical Oncology, J&J unveiled three studies of its drug Rybrevant in different patient groups with non-small cell lung cancer with EGFR mutations. All were successful, with the drug, sometimes used in combination with other therapies, helping stave off progression of the disease.

In an interview, Mark Wildgust, J&J’s vice president of global medical affairs for oncology, framed the totality of the research as a case that Rybrevant could become a regularly used treatment for these patients.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Pumping milk in bathrooms at health conferences is common

WSS

A pediatrician calls for Congress to pass the child tax credit deal

TikTok, Instagram influencers need more rules for drug ads

Cardiologists urge adding sexual orientation, gender identity to health records

There's an unseen cost to disruptive road

FDA endorses new sterilization method for medical devices

UnitedHealth starts bidding war with $3.3 billion offer for Amedisys

hotspot

explore

leisure time

Supreme Court strikes down use of affirmative action

Why do we get seasonal allergies?

Tori Bowie and the unacceptable rates of Black maternal death

Update the Apgar Score to remove skin color

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Printout prescription drug information shouldn’t go digital

Continuity nursing helped my family in our darkest PICU moments

FDA sets aggressive timeline for overhauling inspection procedures

Virginia high school admissions case could be legal follow

Prince Harry seeks over $550,000 in phone hacking lawsuit against British tabloid publisher

entertainment

Update the Apgar Score to remove skin color

Maisha Meds is a PBM, but don't call it that

GOP hopefuls to address prominent, controversial group questioning what's taught in schools

GOP hopefuls to address prominent, controversial group questioning what's taught in schools

FDA endorses new sterilization method for medical devices

Microsoft launches AI tool for clinical documentation through Epic

focus

leisure time

hotspot

Wikipedia